Interleukin-2 biobetter - Biolingus

Drug Profile

Interleukin-2 biobetter - Biolingus

Alternative Names: SLIT-IL-2-Biolingus

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vitapharm Technology Development
  • Developer Biolingus; Vitapharm Technology Development
  • Class Anti-infectives; Antiallergics; Biobetters; Interleukins; Lymphokines; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Peanut hypersensitivity; Tuberculosis; Type 1 diabetes mellitus
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 12 Sep 2017 Interleukin-2 biobetter - Biolingus is available for licensing as of 12 Sep 2017.
  • 11 Sep 2017 Discontinued - Preclinical for Cancer in China (Sublingual)
  • 11 Sep 2017 Discontinued - Preclinical for Rheumatoid arthritis in China (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top